[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100602243":3},{"organization":4,"armGroups":7,"interventions":45,"overallOfficials":76,"centralContacts":80,"locations":86,"responsibleParty":107,"collaborators":51,"id":110,"slug":111,"hasResults":112,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":51,"eligibilityCriteria":116,"healthyVolunteers":112,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":51,"studyType":123,"phases":124,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":89,"whyStopped":51,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8,14,18,22,26,30,34,38,42],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 0 - Cohort 1","EXPERIMENTAL","5mg\u002Fkg\u002Fday in two divided doses for three days",[13],"Drug: Metformin (open-label)",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 0 - Cohort 2","10mg\u002Fkg\u002Fday in two divided doses for three days",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Phase 0 - Cohort 3","20mg\u002Fkg\u002Fday in two divided doses for seven days",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Phase 0 - Cohort 4","25mg\u002Fkg\u002Fday in two divided doses for 14 days",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Phase 1 - Cohort 1 Escalation","15mg\u002Fkg\u002Fday in a single daily dose for three days",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"Phase 1 - Cohort 2 Escalation","25mg\u002Fkg\u002Fday in a single daily dose for three days",[13],{"label":35,"type":10,"description":36,"interventionNames":37},"Phase 1- Cohort 3 Escalation","10mg\u002Fkg\u002Fday in a single daily dose for three days",[13],{"label":39,"type":10,"description":40,"interventionNames":41},"Phase 1 - Cohort 4 Expansion","10-25mg\u002Fkg\u002Fday (dose selected from either Cohort 2 or 3)",[13],{"label":43,"type":10,"description":40,"interventionNames":44},"Phase 1 - Cohort 5 Expansion",[13],[46,52,55,58,61,64,67,70,73],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":51},"DRUG","Metformin (open-label)","Enteric metformin 5mg\u002Fkg\u002Fday in two divided doses will be given for three days to two subjects",[9],null,{"type":47,"name":48,"description":53,"armGroupLabels":54,"otherNames":51},"Enteric metformin 10mg\u002Fkg\u002Fday in two divided doses will be given for three days to two subjects.",[15],{"type":47,"name":48,"description":56,"armGroupLabels":57,"otherNames":51},"Enteric metformin 20mg\u002Fkg\u002Fday in two divided doses will be given for seven days to three subjects.",[19],{"type":47,"name":48,"description":59,"armGroupLabels":60,"otherNames":51},"Enteric metformin 25mg\u002Fkg\u002Fday in two divided doses will be given for 14 days to three subjects.",[23],{"type":47,"name":48,"description":62,"armGroupLabels":63,"otherNames":51},"Enteric metformin 15mg\u002Fkg\u002Fday in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, the next Cohort will increase to 25mg\u002Fkg\u002Fday (Cohort 2) or decrease to 10mg\u002Fkg\u002Fday (Cohort 3)",[27],{"type":47,"name":48,"description":65,"armGroupLabels":66,"otherNames":51},"Enteric metformin 25mg\u002Fkg\u002Fday in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 25mg\u002Fkg\u002Fday or 15mg\u002Fkg\u002Fday will be dose selected for the next Cohort (Cohort 4)",[31],{"type":47,"name":48,"description":68,"armGroupLabels":69,"otherNames":51},"Enteric metformin 10mg\u002Fkg\u002Fday in a single daily dose will be given for three days to 3-6 subjects. Depending on tolerance, either 10mg\u002Fkg\u002Fday dose selected for the next Cohort (Cohort 4) or the study will be stopped due to excessive toxicity.",[35],{"type":47,"name":48,"description":71,"armGroupLabels":72,"otherNames":51},"The dose for this cohort will be selected from either Cohort 2 or 3 based on tolerance. Enteric metformin 10-25mg\u002Fkg\u002Fday in a single daily dose will be given for seven days to 6 subjects.",[39],{"type":47,"name":48,"description":74,"armGroupLabels":75,"otherNames":51},"The dose for this cohort will be the same as Cohort 4. Enteric metformin 10-25mg\u002Fkg\u002Fday in a single daily dose will be given for 14 days to 6 subjects.",[43],[77],{"name":78,"affiliation":5,"role":79},"G. Ganesh Konduri, MD, MS","PRINCIPAL_INVESTIGATOR",[81],{"name":82,"role":83,"phone":84,"phoneExt":51,"email":85},"Kathleen Meskin, BSN, RN, CCRP","CONTACT","414-337-7171","kmeskin@mcw.edu",[87],{"facility":88,"status":89,"city":90,"state":91,"zip":92,"country":93,"countryCode":94,"cosmosGeoPoint":95,"geoPoint":100,"contacts":101},"Children's Wisconsin","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":96,"coordinates":97},"Point",[98,99],-87.90647,43.0389,{"lat":99,"lon":98},[102,103,104],{"name":82,"role":83,"phone":84,"phoneExt":51,"email":85},{"name":78,"role":79,"phone":51,"phoneExt":51,"email":51},{"name":105,"role":106,"phone":51,"phoneExt":51,"email":51},"Ru-Jeng Teng, MD","SUB_INVESTIGATOR",{"type":79,"investigatorFullName":108,"investigatorTitle":109,"investigatorAffiliation":5,"oldNameTitle":51,"oldOrganization":51},"G. Ganesh Konduri","Professor, Division Chief of Neonatology","100602243","early-phase-1-metformin-for-premature-infants-with-bronchopulmonary-dysplasia-100602243",false,"NCT07120971","Metformin for Premature Infants With Bronchopulmonary Dysplasia","A Phase 0\u002FPhase 1 Trial of Metformin for Premature Infants With Bronchopulmonary Dysplasia","Inclusion Criteria Phase 0:\n\n* Birth gestational age of \\\u003C 29 weeks AND\n* Postnatal age between 8 and 22 weeks AND\n* Diagnosed with BPD at 36 weeks postnatal age\n\nInclusion Criteria Phase 1:\n\n* Birth gestational age of \\\u003C 29 weeks, AND\n* Requiring mechanical ventilation or positive pressure support at 7 days postnatal age, AND\n* Postnatal age between 7 and 30 days\n\nExclusion Criteria:\n\n* Persistent hypoglycemia\n* Lactic acidosis\n* Feeding intolerance\n* Renal or hepatic dysfunction\n* Active infection\n* Congenital anomalies that preclude feedings\n* Infants whose parents have chosen palliative care","ALL","7 Days","6 Months",{"count":121,"type":122},40,"ESTIMATED","INTERVENTIONAL",[125],"EARLY_PHASE1","The overall objective of this study is to investigate the role of metformin in decreasing lung injury and promoting lung growth in premature infants. There are two phases to this pilot study. For Phase 0, the goal is to investigate the safety and tolerance of oral metformin in premature who have been diagnosed with bronchopulmonary dysplasia (BPD) at 36-44 weeks gestation. For Phase 1, the goal is to investigate metformin safety and tolerance in extremely premature infants who are 7-30 days old who have an increased risk of BPD. The main questions it aims to answer are:\n\n* how well do older premature infants tolerate metformin?\n* how well do younger premature infants tolerate metformin?",[128],"Bronchopulmonary Dysplasia (BPD)",[130,131,132,133],"bronchopulmonary dysplasia","BPD","prematurity","metformin","2026-01-23",{"date":136,"type":137},"2026-01-26","ACTUAL",{"date":139,"type":137},"2025-12-19",{"date":141,"type":122},"2030-09-01",{"name":5,"class":6},1]